Lars L. Gullestad
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Lars L. Gullestad

Oslo, NO 
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Oslo, NO 
OverviewLocationsClinical Research

Overview

Lars Gullestad practices in Oslo, Norway. Mr. Gullestad is rated as an Experienced expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure, Aortic Valve Stenosis, Aortic Regurgitation, Heart Transplant, and Lung Transplant.

His clinical research consists of co-authoring 302 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender
Male

Locations

Oslo, Norway
Other Locations
Nydalen, 0424, Norway
Blindern, 0316, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis: The IIISAS Trial
Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis: The IIISAS Trial
Enrollment Status: Unknown
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: Iron Isomaltoside
Study Phase: Phase 2
Sleep Disordered Breathing in Patients With Paroxysmal Atrial Fibrillation
Sleep Disordered Breathing in Patients With Paroxysmal Atrial Fibrillation
Enrollment Status: Completed
Publish Date: June 22, 2021
Intervention Type: Device
Study Phase: Not Applicable
High Intensity Training in de Novo Heart Transplant Recipients in Scandinavia
High Intensity Training in de Novo Heart Transplant Recipients in Scandinavia
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Behavioral
Study Phase: Not Applicable
5, 6 or 7 Year Follow-up Control After the SCHEDULE Study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE)
5, 6 or 7 Year Follow-up Control After the SCHEDULE Study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE)
Enrollment Status: Completed
Publish Date: October 03, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

302 Total Publications

High levels of the adipokines leptin and metrnl in patients with paroxysmal atrial fibrillation and obstructive sleep apnea are not associated with the severity of sleep apnea or the burden of atrial fibrillation.
High levels of the adipokines leptin and metrnl in patients with paroxysmal atrial fibrillation and obstructive sleep apnea are not associated with the severity of sleep apnea or the burden of atrial fibrillation.
Journal: Sleep medicine
Published: July 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gullestad's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile